secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2024-10-28T23:59:59+00:00
Accession:  0001818382-24-000192
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte ATEV meets Phase 3 co-primary endpoints; superior to AV fistula in hemodialysis
--------------------------------------------------------------------------------

- ATEV showed functional patency 81.3% at 6 months vs 66.4% for AV fistula; secondary patency 68.3% vs 62.2% at 12 months (joint p=0.0071).
- Subgroup analyses: ATEV superior in female (p<0.0001), obese (p=0.0001), and diabetic (p=0.0024) patients for patency rates and hemodialysis duration.
- Thrombosis reported in 52.1% of ATEV patients vs 9.1% for AV fistula; 94% of thrombotic events successfully treated.
- Infection rates low and similar: 9.1% ATEV vs 9.9% AV fistula.
- Phase 3 trial enrolled 242 hemodialysis patients in US; ATEV is investigational and not yet FDA-approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838224000192/0001818382-24-000192-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838224000192/huma-20241028.htm
  HTML page:      https://secwatch.observer/filing/0001818382-24-000192

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer